Similarly, a patient cohort at the Dana Farber Cancer Institute, including 266 patients with advanced NSCLC who were treated with PD-(L)1 inhibitors, demonstrated the presence of pathologic DDR alterations in 49.6% of patients, with the most common mutations involving ATM, ATR, BRCA2, POLQ, and RAD50 [33] (Figure 2). This evidence concerns the gene BRCA2 and non-small cell lung carcinoma.